Drug Trial Radar · NCT04966559
Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis
Last checked: Nov 20, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
74
Actual
Start
Jan 12, 2022
Primary completion
Mar 30, 2024
Study completion Jun 1, 2024
Sponsor
- Lead sponsor
- Asbjørn Mohr DrewesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Odense University Hospital; Hvidovre University Hospital; University Hospital Bispebjerg and Frederiksberg; Karolinska University Hospital
- First posted
- Jul 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the effect of a peripheral acting opioid antagonist (PAMORA) on the disease course of patients with recurrent acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating outpatients suffering from recurrent acute pancreatitis with a PAMORA (naldemedine) for 12 months.
Conditions
- Pancreatitis, Acute
Interventions
Placebo treatmentDrug
Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Naldemedine 0.2 MG Oral TabletDrug
Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of AP attacks verified by the Atlanta CriteriaTime frame: Observation period starts from day of randomization and ends after a minimum of 6 months and a maximum of 12 months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Digestive Disease Center K, Bispebjerg University Hospital
Bispebjerg, Denmark
Gastrounit, Hvidovre University Hospital
Hvidovre, Denmark
Odense Pancreas Center
Svendborg, Denmark
Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital
Aalborg, Jutland, Denmark
Karolinska University Hospital
Stockholm, Solna (l1:00), Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.